Caisse de depot et placement du Quebec Takes Position in Bristol Myers Squibb Company $BMY

Caisse de depot et placement du Quebec purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,228,503 shares of the biopharmaceutical company’s stock, valued at approximately $243,646,000.

A number of other institutional investors and hedge funds have also bought and sold shares of BMY. Swiss RE Ltd. purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter worth approximately $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at about $25,000. Davis Asset Management L.P. acquired a new stake in Bristol Myers Squibb in the 2nd quarter worth approximately $27,000. Bayban purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the fourth quarter valued at about $32,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Down 0.4%

Bristol Myers Squibb stock opened at $67.68 on Thursday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The company has a market cap of $138.25 billion, a PE ratio of 14.91, a price-to-earnings-growth ratio of 0.18 and a beta of 0.22. The stock’s 50 day moving average price is $61.25 and its 200 day moving average price is $59.60.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the previous year, the company earned $1.46 EPS. The company’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is currently 55.51%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BMY. Citigroup reiterated a “neutral” rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Royal Bank Of Canada upped their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. raised their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Piper Sandler started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued an “overweight” rating on the stock. Finally, Wells Fargo & Company set a $65.00 price objective on Bristol Myers Squibb and gave the stock an “equal weight” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb has an average rating of “Moderate Buy” and an average price target of $66.06.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.05% of the stock is currently owned by company insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.